Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cue Biopharma (Nasdaq:CUE), a clinical-stage therapeutics company developing therapies for immunological disorders, announced that president and CEO Shao-Lee Lin will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City.
A live audio webcast, replay, and 90-day archive will be available on Cue Biopharma’s investor relations website.
Details
News Market Reaction – CUE
On May 22, the first trading day after this news, CUE closed 6.82% above the previous close.
Data tracked by StockTitan Argus for the May 22 session.
Key Figures
- Conference date
- June 3, 2026
- Jefferies Global Healthcare Conference presentation date
- Presentation time
- 3:10 p.m. EDT
- Scheduled time for Cue Biopharma’s conference presentation
- Webcast archive period
- 90 days
- Length of time the conference webcast replay will be available
Historical Context
-
Higher collaboration revenue, narrower net loss, but shares fell post-release.
-
Equity awards to new CEO and hires under Nasdaq inducement rule.
-
$30M private placement via warrants to fund pipeline and Ascendant-221.
-
Exclusive global license for Phase 2 anti-IgE Ascendant-221, milestones, royalties.
-
Appointment of Shao-Lee Lin as CEO to lead clinical-stage transition.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
immunological disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City.
A live audio webcast and replay of the presentation will be available through Cue Biopharma’s Investor Relations website. The webcast will be archived for 90 days.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor and Media Contact
Agnes Lee
Chief Officer of Public and Investor Relations
Marie Campinell
Senior Director, Corporate Communications
ir@cuebio.com
Cue Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.